MA45888A1 - Inhibiteurs de tyrosine kinase de bruton - Google Patents

Inhibiteurs de tyrosine kinase de bruton

Info

Publication number
MA45888A1
MA45888A1 MA45888A MA45888A MA45888A1 MA 45888 A1 MA45888 A1 MA 45888A1 MA 45888 A MA45888 A MA 45888A MA 45888 A MA45888 A MA 45888A MA 45888 A1 MA45888 A1 MA 45888A1
Authority
MA
Morocco
Prior art keywords
independently
alkyl
hal
fragment
group
Prior art date
Application number
MA45888A
Other languages
English (en)
Inventor
Pavel Andreevich Iakovlev
Aleksey Sergeevich Gavrilov
Pavel Aleksandrovich Aleshunin
Svetlana Leonidovna Gorbunova
Mikhail Vladimirovich Rekharsky
Natalia Vladimirovna Kozhemyakina
Anna Aleksandrovna Kukushkina
Anna Sergeevna Kushakova
Leonid Evgen`Evich Mikhaylov
Alexander Moldavsky
Aleksandra Vladimirovna Popkova
Sergey Aleksandrovich Silonov
Svetlana Sergeevna Smirnova
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA45888A1 publication Critical patent/MA45888A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un nouveau composé représenté par la formule i, ou un sel, un solvate ou un stéréoisomère pharmaceutiquement acceptable de celui-ci, dans laquelle : v1 est c ou n, v2 est c(r2) ou n, ainsi si v1 est c alors v2 est n, si v1 est c alors v2 est c(r2), ou si v1 est n alors v2 est c(r2); chaque n, k est indépendamment 0, 1; chaque r2, r11 est indépendamment h, d, hal, cn, nr'r", c(o)nr'r", un alkoxy c1-c6; r3 est h, d, un hydroxy, un alkyle en c(o)c1-c6, un alcényle en c(o)c2-c6 , un alcényle en c(o)c2-c6, un alkyle en c1-c6; r4 est h, hal, cn, conr'r", un hydroxy, un alkyle en c1-c6, un alkoxy c1-c6; l est ch2, nh, o ou une liaison chimique; r1 est choisi dans le groupe de fragments, comprenant : fragment 1, fragment 2, fragment 3 chaque a1, a2, a3, a4 est indépendamment ch, n, chal; chaque a5, a6, a7, a8, a9 est indépendamment c, ch ou n; r5 est h, cn, hal, conr'r", un alkyle en c1-c6, non substitué ou substitué par un ou plusieurs halogènes; chaque r' et r" est indépendamment sélectionné dans le groupe comprenant, h, un alkyle en c1-c6, un cycloalkyle en c1-c6, un aryle; r6 est sélectionné dans le groupe : [formule ii] chaque r7, r8, r9, r10est indépendamment un vinyle, un méthylacétylényle; hal est ci, br, i, f, qui possèdent des propriétés d'un inhibiteur de tyrosine kinase de bruton (btk), la présente invention concerne également des compositions pharmaceutiques contenant lesdits composés, et leur utilisation en tant qu'agents pharmaceutiques dans le traitement de maladies et troubles.
MA45888A 2016-11-18 2017-11-16 Inhibiteurs de tyrosine kinase de bruton MA45888A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662424041P 2016-11-18 2016-11-18
PCT/IB2017/057154 WO2018092047A1 (fr) 2016-11-18 2017-11-16 Inhibiteurs de tyrosine kinase de bruton

Publications (1)

Publication Number Publication Date
MA45888A1 true MA45888A1 (fr) 2020-06-30

Family

ID=60574666

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45888A MA45888A1 (fr) 2016-11-18 2017-11-16 Inhibiteurs de tyrosine kinase de bruton

Country Status (19)

Country Link
US (1) US20190352276A1 (fr)
EP (1) EP3541811A1 (fr)
JP (1) JP2019537611A (fr)
KR (1) KR20190104516A (fr)
CN (1) CN110177781A (fr)
AU (1) AU2017362066A1 (fr)
BR (1) BR112019009945A2 (fr)
CA (1) CA3043297A1 (fr)
CL (1) CL2019001330A1 (fr)
CR (1) CR20190261A (fr)
EA (1) EA201990902A1 (fr)
EC (1) ECSP19043231A (fr)
JO (1) JOP20190113A1 (fr)
MA (1) MA45888A1 (fr)
MX (1) MX2019005706A (fr)
PE (1) PE20191082A1 (fr)
PH (1) PH12019550083A1 (fr)
WO (1) WO2018092047A1 (fr)
ZA (1) ZA201903694B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793566B2 (en) * 2016-01-21 2020-10-06 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
KR102384924B1 (ko) * 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
WO2019013562A1 (fr) * 2017-07-12 2019-01-17 주식회사 대웅제약 Nouveau dérivé de 1h-pyrazolopyridine et composition pharmaceutique le contenant
CA3108065C (fr) 2018-07-31 2025-10-07 Loxo Oncology, Inc. Dispersions séchées par pulvérisation, formulations et polymorphies de (s)-5-amino-3-(4-((5 fluoro-2-méthoxybenzamido)méthyle)phényle)(1,1,1-trifluoropropane-2-yl)-1h-pyrazole-4-carboxamide
US11739090B2 (en) 2019-09-26 2023-08-29 Jumbo Drug Bank Co., Ltd. Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors
US12486274B2 (en) 2020-01-13 2025-12-02 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
MX2023001997A (es) * 2020-08-17 2023-05-12 Betta Pharmaceuticals Co Ltd Compuestos biciclicos, composiciones y usos de los mismos.
CN114478519B (zh) * 2020-10-23 2024-06-11 励缔(杭州)医药科技有限公司 吡唑并吡啶类化合物或其盐及其制备方法和用途
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022228302A1 (fr) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Composés carboxamides hétéroaromatiques et leur utilisation
WO2025202889A1 (fr) * 2024-03-28 2025-10-02 Array Biopharma Inc. Inhibiteurs de mutation de her2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2139487B1 (fr) * 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibiteurs de la tyrosine kinase de bruton
WO2011019780A1 (fr) * 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles comme modulateurs de la kinase btk et leur utilisation
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP2548877A1 (fr) * 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
CN104603124B (zh) * 2012-08-10 2018-04-17 勃林格殷格翰国际有限公司 用作布鲁顿酪氨酸激酶(btk)抑制剂的杂芳族化合物
US9637486B2 (en) * 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
SG11201605417QA (en) * 2014-02-03 2016-08-30 Cadila Healthcare Ltd Heterocyclic compounds
CA2959602A1 (fr) * 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
AU2017208998B2 (en) * 2016-01-21 2021-07-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Bruton's tyrosine kinase inhibitors
EP3426637B1 (fr) * 2016-03-11 2022-02-09 Angel Pharmaceutical Co., Ltd. Composés et procédés pour moduler la tyrosine kinase de bruton

Also Published As

Publication number Publication date
AU2017362066A1 (en) 2019-05-30
ECSP19043231A (es) 2019-06-30
PE20191082A1 (es) 2019-08-20
CL2019001330A1 (es) 2019-09-27
EP3541811A1 (fr) 2019-09-25
EA201990902A1 (ru) 2019-11-29
ZA201903694B (en) 2021-04-28
MX2019005706A (es) 2019-07-08
US20190352276A1 (en) 2019-11-21
JOP20190113A1 (ar) 2019-05-15
CA3043297A1 (fr) 2018-05-24
BR112019009945A2 (pt) 2019-08-13
KR20190104516A (ko) 2019-09-10
CN110177781A (zh) 2019-08-27
WO2018092047A1 (fr) 2018-05-24
PH12019550083A1 (en) 2020-03-09
JP2019537611A (ja) 2019-12-26
CR20190261A (es) 2019-09-02

Similar Documents

Publication Publication Date Title
PH12019550083A1 (en) Inhibitors of bruton's tyrosine kinase
MA49952B1 (fr) Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
MA58181B1 (fr) Composés tricycliques substitués
ZA202108263B (en) Imidazolonylquinoline compounds and therapeutic uses thereof
MX2020011501A (es) Compuestos novedosos.
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
EP4371562A3 (fr) Dérivés de la 2-quinolone en tant qu'inhibiteurs du récepteur bcl6
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
WO2019007696A1 (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
MA41494B1 (fr) Composés benzoxaborole substitués en position 4 et utilisations associées
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MA49127B1 (fr) Dérivés d'indole n-substitués
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
SA520420382B1 (ar) مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MA44965B1 (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
EA202191349A1 (ru) 1,3,4-оксадиазолон и фармацевтический препарат
MA27795A1 (fr) Derives d'amine cycliques, procedes de preparation de ceux-ci et compositions pharmaceutiques les contenant